Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsUnited Therapeutics Corporation (UTHR)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$12.26
+1.57%
HEALTHCARE · Cap: $3.80B
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 5% more annual revenue ($3.18B vs $3.02B). UTHR leads profitability with a 41.9% profit margin vs 2.4%. UTHR trades at a lower P/E of 19.4x. UTHR earns a higher WallStSmart Score of 67/100 (B-).
AMRX
Hold46
out of 100
Grade: D+
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-42.7%
Fair Value
$10.30
Current Price
$12.26
$1.96 premium
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
2.6% earnings growth
2.4% margin — thin
Premium valuation, high expectations priced in
ROE of -8.8% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
Revenue growth of 11.5% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : AMRX
The primary concerns for AMRX are EPS Growth, Profit Margin, P/E Ratio. A P/E of 54.9x leaves little room for execution misses. Thin 2.4% margins leave little buffer for downturns.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
AMRX profiles as a value stock while UTHR is a mature play — different risk/reward profiles.
AMRX carries more volatility with a beta of 1.30 — expect wider price swings.
AMRX is growing revenue faster at 11.5% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 46/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?